Related Experiment Video
Updated: May 6, 2026
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Respiratory syncytial virus detection in cells and clinical samples by using three new monoclonal antibodies
Roberto S Gómez1, Jorge E Mora, Claudia M Cortés
1Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile; INSERM U1064, Nantes, France.
Insights
New monoclonal antibodies (mAbs) offer a rapid and reliable method for detecting respiratory syncytial virus (RSV) in clinical samples. These advanced diagnostic tools show high specificity and sensitivity for identifying RSV infections in infants and adults.
Area of Science:
- Virology
- Immunology
- Diagnostic Medicine
Background:
- Respiratory syncytial virus (RSV) infections pose a significant global health burden, particularly for infants, causing substantial morbidity and economic losses.
- Current diagnostic methods for RSV, including immunofluorescence, test packs, and PCR, have limitations, highlighting the need for improved diagnostic tools.
- The development of novel monoclonal antibodies (mAbs) is crucial for creating faster and more accurate RSV detection methods.
Purpose of the Study:
- To evaluate the efficacy of three newly developed monoclonal antibodies (mAbs) targeting RSV N and M2-1 proteins.
- To assess the diagnostic potential of these mAbs for detecting RSV in clinical samples and infected cells.
Main Methods:
- Nasopharyngeal swabs were collected from RSV-positive patients, human metapneumovirus (hMPV)-positive patients, and healthy controls.
- Enzyme-Linked ImmunoSorbent Assay (ELISA), flow cytometry, immunofluorescence, and dot-blot assays were employed to test clinical samples and RSV-infected cells.
- Specificity and sensitivity of the mAbs were determined using purified RSV antigens and antigens from other viruses.
Main Results:
- The three new anti-RSV mAbs successfully detected RSV in infected cells and clinical samples across all tested immunological methods (immunofluorescence, ELISA, flow cytometry, dot blot).
- The mAbs demonstrated high specificity, yielding no false positives in samples infected with hMPV or from healthy controls.
- The evaluated mAbs show promise for accurate RSV detection.
Conclusions:
- The newly developed anti-RSV mAbs are effective for the rapid and reliable detection of RSV.
- These mAbs can be utilized in various immunological approaches for diagnosing RSV in clinical specimens and infected cells.
- The findings support the use of these mAbs in developing improved diagnostic tools for RSV.
Abstract:
Acute respiratory infections caused by the respiratory syncytial virus (RSV) are important health burdens that affect infants worldwide. RSV is also an important cause of morbidity and disease in adults, which causes enormous economic losses. At the present time, RSV infection is diagnosed by immunofluorescence, test pack and/or PCR, obtaining better results with PCR than with any other technique. The production of new monoclonal antibodies (mAbs) capable of detecting RSV in clinical samples is necessary to generate better and faster diagnosis tools for RSV. In this study, three new mAbs, directed against the RSV N and M2-1 proteins, were evaluated for the detection of RSV in clinical samples. Nasopharyngeal swabs were obtained from: 27 RSV-positive patients; 15 human metapneumovirus (hMPV)-positive patients; and 6 healthy controls. To evaluate RSV presence in these samples, clinical samples and RSV-infected cells were tested by Enzyme-Linked ImmunoSorbent Assay (ELISA), flow cytometry, immunofluorescence, and dot-blot assays. Specificity and sensitivity were determined for each mAb by using purified RSV antigens and antigens from different viruses. Infected cells and clinical samples tested with the three new mAbs resulted positive by immunofluorescence, ELISA, flow cytometry, and dot blot. No false positives were obtained in samples infected with other respiratory virus (hMPV) or from healthy controls. These results suggest that these new anti-RSV mAbs can be considered for the rapid and reliable detection of RSV on infected cells and clinical specimens by multiple immunological approaches.
